Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain [Seeking Alpha]
Dynavax Technologies Corporation (DVAX)
Last dynavax technologies corporation earnings: 3/11 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.dynavax.com
Company Research
Source: Seeking Alpha
Dynavax's shingles and Tdap vaccines advanced in clinical stages, with data anticipated in the coming quarters. Dynavax's balance sheet remains robust with a significant cash runway. Dynavax remains a "hold," given the challenging prospects beyond the hepatitis B market. Dynavax Approaches Profitability with HEPLISAV-B Growth Dynavax NASDAQ: DVAX ) markets HEPLISAV-B, a vaccine for the prevention of hepatitis B. This vaccine was originally approved in 2017. Moreover, the company's pipeline includes Phase 1/2 vaccines for pertussis-Tdap, shingles, and plague. My last analysis of Dynavax in October focused on their Q2 2023 earnings report. Within it, HEPLISAV-B saw a sales surge of 73% year over year, prompting Dynavax to boost their full-year guidance. However, despite a strong liquidity position, Dynavax remained some ways away from profitability and its prospects beyond hepatitis B were uninspiring. My recommendation was "hold." Dynavax's stock is down 20% since then. Catc
Show less
Read more
Impact Snapshot
Event Time:
DVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DVAX alerts
High impacting Dynavax Technologies Corporation news events
Weekly update
A roundup of the hottest topics
DVAX
News
- TwoStep Therapeutics Launches with Funding to Advance Broadly Applicable Targeting Platform for Solid Tumors [Yahoo! Finance]Yahoo! Finance
- Dynavax to Present at Upcoming Investor ConferencesPR Newswire
- Dynavax Technologies Co. (NASDAQ: DVAX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Dynavax Technologies Co. (NASDAQ: DVAX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- UPDATE 1-US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine [Yahoo! Finance]Yahoo! Finance
DVAX
Earnings
- 5/8/24 - Miss
DVAX
Analyst Actions
- 5/9/24 - HC Wainwright
DVAX
Sec Filings
- 6/3/24 - Form 4
- 5/28/24 - Form 4
- 5/28/24 - Form 4
- DVAX's page on the SEC website